

Attorney Docket No.: 6161.200-US
USSN: 09/867,277
Filed: May 29, 2001
Inventor: Lars Peter Klitmose


Remarks

Claims 1-45 have been cancelled. New claims 46-49 contain the essential element of old claim 43, which the Examiner deemed allowable. In fact, claim 46 is a rewriting of claim 43 in independent form with the incorporation of the base claim 42. Claims 47 and 48 depend from claim 46 and should therefore be allowable. Claim 49 is a more precise recitation of the essential elements of the old allowable claim 43 and should therefore also be allowable.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this response or application.

Respectfully submitted,

Date: November 23, 2004



Marc A. Began, Reg. No. 48,829
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

Use the following customer number for all correspondence regarding this application.

23650

PATENT TRADEMARK OFFICE